Skip to main content
Celcuity Inc. logo

Celcuity Inc. - Investor Relations & Filings

Listed IPO Sep 2017
Ticker · CELC ISIN · US15102K1007 LEI · 25490070W7UU7W2SEY87 US Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2025-11-13 Interim / Quarterly Rep…
Country US United States of America
Listing US CELC · 7 venues

About Celcuity Inc.

https://www.celcuity.com/

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company's approach centers on the PI3K/AKT/mTOR (PAM) pathway, a critical signaling cascade involved in cancer cell growth and survival. Its lead product candidate, gedatolisib, is a potential first-in-class, pan-PI3K and mTORC1/2 inhibitor designed to comprehensively blockade the PAM pathway. Celcuity's pipeline is advancing treatments with a focus on breast and prostate cancers.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report 9M 2025
2025-11-13 English
Q3 2025
Call Transcript Classification · 100% confidence The document is a verbatim transcript of a conference call, indicated by the presence of speaker names (e.g., 'Brian Sullivan', 'Vicky Hahne'), Q&A session references, and introductory remarks typical of an earnings call. It covers financial results and business updates for Q3 2025. According to the filing definitions, a full verbatim transcript of an earnings or conference call is classified as a Call Transcript (CT).
2025-11-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release about the company's financial results for the third quarter ended September 30, 2025. The document states that the press release is furnished as an exhibit and is incorporated by reference, and the information is being furnished, not filed, indicating it is an announcement rather than a full financial report. The document length is 4171 characters, which is relatively short and consistent with a current report rather than a full quarterly or annual report. Given these factors, the document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full financial statements or detailed analysis required for an Interim/Quarterly Report (IR) or Annual Report (10-K).
2025-11-12 English
Stifel 2025 Healthcare Conference
Call Transcript Classification · 100% confidence The document is a verbatim transcript of a Q&A session between a biotech analyst (Stephen Willey) and a company CEO (Brian Sullivan) at the Stifel 2025 Healthcare Conference. It features speaker names, direct dialogue, and detailed discussion regarding clinical trial data, drug development strategy, and market positioning. This fits the definition of a Call Transcript (CT).
2025-11-11 English
Study Result
Call Transcript Classification · 100% confidence The document is a verbatim transcript of a conference call, indicated by the presence of a conference operator ('Bella'), speaker introductions ('Brian Sullivan, CEO', 'Dr. Igor Gorbatchevsky'), and instructions for a Q&A session ('press star, then the number one'). The content discusses clinical trial results (VIKTORIA-1) and references slide numbers, which is characteristic of an earnings or investor conference call transcript.
2025-10-20 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or disclosures by a company. The content focuses on clinical trial results, regulatory updates, and press releases related to the company's drug development progress. It includes detailed clinical trial data and forward-looking statements but does not contain comprehensive financial statements or annual performance data. The document is not an earnings release, annual report, or interim report. It is primarily a regulatory announcement of significant clinical trial results and related events. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-20 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.